Estudo de utilização de inibidores de bomba de prótons por usuários de farmácias comunitárias

• Ano de defesa: 2021
• Autor(a) principal: Araújo, Lorena Maria Lima de
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Universidade Federal do Rio Grande do Norte; Brasil; UFRN; PROGRAMA DE PÓS-GRADUAÇÃO EM CIÊNCIAS FARMACÊUTICAS
• Palavras-chave em Português: Inibidores da bomba de prótons; Estudo de utilização de medicamentos; Farmácia comunitária
• Link de acesso: https://repositorio.ufrn.br/handle/123456789/32814

Proton pump inhibitors (PPIs) are among the most prescribed drugs in the world. However, information on user profiles and factors associated with their purchase at community pharmacies is scarce. The aim of this study is to characterize the pattern of PPI use and factors associated with inappropriate use and prolonged use. A crosssectional, prospective and observational study was conducted involving interviews with 410 patients who purchased PPIs for their own use in community pharmacies. The socio-demographic and clinical profile (diseases and other medications) is being investigated. Regarding PPIs and their use, the indication for use, dosage adopted, time and patient knowledge about the drug and pharmacoeconomic aspects are being evaluated. We are using descriptive statistics for sample characterization and multivariate logistic regression model to determine factors associated with PPI use. Results point to an adequate use of PPI regarding indication and form of use (79%), however there is a high prevalence of prolonged use of these drugs (30%) associated with lack of knowledge about adverse reactions (57%). The selection of the PPI does not consider the purchasing power of the patient, with lower HDI neighborhoods presenting the cost of PPI treatment similar to the most economically developed locations in the city. Therefore, PPI use is adequate as to indication and form of use, however, it is used for prolonged periods without knowledge of the risks and existing PDIs, as well as a discrepancy in the prescription between patient's purchasing power and cost of treatment.